Basics Myriad Genetics, Inc. Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs. IPO Date: October 6, 1995 Sector: Healthcare Industry: Biotech Market Cap: $382.54M Activated in VL: True Average Daily Range Avg Daily Range: $0.50 | 1.89% Avg Daily Range (30 D): $0.23 | 4.26% Avg Daily Range (90 D): $0.29 | 3.40% Institutional Daily Volume Avg Daily Volume: .83M Avg Daily Volume (30 D): 2.4M Avg Daily Volume (90 D): 1.4M Trade Size Avg Trade Size (Sh.): 123 Avg Trade Size (Sh.) (30 D): 113 Avg Trade Size (Sh.) (90 D): 90 Institutional Trades Total Inst.Trades: 11,585 Avg Inst. Trade: $1.86M Avg Inst. Trade (30 D): $2.05M Avg Inst. Trade (90 D): $1.89M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.53M Avg Closing Trade (30 D): $2.3M Avg Closing Trade (90 D): $2.15M Avg Closing Volume: 104.26K         News May 8, 2025 @ 9:28 PM Securities Fraud Investigation Into Myriad Genetic... Source: Business Wire May 8, 2025 @ 7:51 PM Myriad Genetics, Inc. (MYGN) Investors Who Lost Mo... Source: Business Wire May 8, 2025 @ 6:54 PM Tissue Diagnostics Market to Reach $12.4 Billion b... Source: Bcc Research May 1, 2025 @ 5:00 PM Global Molecular Diagnostics Market to Expand at a... Source: Delveinsight Apr 23, 2025 @ 5:00 PM Liquid Biopsy in Cancer Diagnostics Market to Grow... Source: Delveinsight Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.12 $ $-.47 Diluted EPS $-1.12 $ $-.47 Revenue $ 831.3M $ 195.9M $ 210.6M Gross Profit $ 582M $ 134.2M $ 150.9M Net Income / Loss $ -101.4M $ -.1M $ -42.5M Operating Income / Loss $ -124.5M $ -29M $ -39M Cost of Revenue $ 249.3M $ 61.7M $ 59.7M Net Cash Flow $ -4.6M $ -10.9M $ 2.1M PE Ratio     Splits Mar 26, 2009:   2:1 Sep 12, 2000:   2:1